-
Lancet (London, England) Nov 1996
Topics: Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radiodermatitis
PubMed: 8909413
DOI: 10.1016/s0140-6736(05)65810-2 -
Clinical and Experimental Dermatology Dec 2021
Topics: COVID-19; COVID-19 Vaccines; Female; Humans; Melanoma; Radiation Dose Hypofractionation; Radiodermatitis; Risk Assessment; SARS-CoV-2
PubMed: 34080223
DOI: 10.1111/ced.14786 -
The Breast Journal Jul 2020
Topics: Breast; Breast Neoplasms; Female; Humans; Quinolones; Radiodermatitis
PubMed: 31999006
DOI: 10.1111/tbj.13756 -
International Journal of Dermatology Sep 2017Radiation therapy has been a commonly employed modality for a variety of ailments, including cancer. Patients undergoing radiation often experience acute and/or chronic... (Review)
Review
Radiation therapy has been a commonly employed modality for a variety of ailments, including cancer. Patients undergoing radiation often experience acute and/or chronic skin changes that can be detrimental to their quality of life. Many topical agents and specialized wound dressings are being used for the prevention and management of radiation-induced skin changes. However, no single therapeutic option has been found to be consistently effective.
Topics: Chronic Disease; Humans; Radiodermatitis; Radiotherapy; Risk Factors; Skin
PubMed: 27496623
DOI: 10.1111/ijd.13371 -
Strahlentherapie Und Onkologie : Organ... May 2016Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to previously irradiated skin, mainly subsequent to the administration of certain... (Review)
Review
BACKGROUND
Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to previously irradiated skin, mainly subsequent to the administration of certain chemotherapeutics. Here we present a rare case of RRD induced by the oral multikinase inhibitor sorafenib.
CASE REPORT
A 77-year-old male with hepatocellular carcinoma was irradiated at ten different sites for bone metastases with 20-36 Gray in 5-12 fractions from January to March 2015. Sorafenib 400 mg was administered twice daily from mid-March. One week later the patient presented with fever and erythematous lesions on the right upper arm, mandible, and trunk. All skin symptoms were confined to previously irradiated areas. After RRD was diagnosed by exclusion of other causes and skin biopsy, sorafenib was paused. With the administration of topical corticosteroids and oral antihistamines, the skin reaction subsided within several days. Sorafenib was readministered after 3 weeks, which did not lead to recurrence of RRD but did cause fluctuating fever.
DISCUSSION
Only four other such cases have been reported in the literature and WHO pharmacovigilance database on individual case safety reports. The current report is the first to show a potential relationship between the severity of sorafenib-induced RRD and radiation dose, histopathological features, and simultaneous acute radiation dermatitis and mucositis.
CONCLUSION
RRD induced by sorafenib is a rare phenomenon, but should be considered in patients showing erythematous skin lesions 1-2 weeks after initiation of the drug, predominantly in areas where skin has been irradiated with an equivalent dose ≥ 30 Gy. Discontinuation of sorafenib with possible readministration should be evaluated with respect to the clinical situation and severity of reaction.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiodermatitis; Radiotherapy, Conformal; Sorafenib; Treatment Outcome
PubMed: 26907093
DOI: 10.1007/s00066-016-0950-7 -
Circulation Sep 2012
Topics: Acetanilides; Aged; Coronary Angiography; Coronary Stenosis; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Male; Piperazines; Radiodermatitis; Ranolazine; Treatment Outcome
PubMed: 22965781
DOI: 10.1161/CIRCULATIONAHA.112.105494 -
American Journal of Therapeutics 2019
Topics: Administration, Cutaneous; Anilides; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Palliative Care; Pyridines; Radiodermatitis; Radiosurgery; Triamcinolone
PubMed: 28816724
DOI: 10.1097/MJT.0000000000000649 -
Journal of Thoracic Oncology : Official... Oct 2020
Topics: Antibodies, Monoclonal, Humanized; Humans; Lung Neoplasms; Pneumonia; Radiation Pneumonitis; Radiodermatitis
PubMed: 32981602
DOI: 10.1016/j.jtho.2020.05.014 -
Strahlentherapie Und Onkologie : Organ... Oct 2016Radiation recall dermatitis (RRD) refers to an acute inflammatory skin reaction appearing on a previously irradiated area following the systemic administration of... (Review)
Review
Radiation recall dermatitis (RRD) refers to an acute inflammatory skin reaction appearing on a previously irradiated area following the systemic administration of a reaction-triggering agent. Despite various hypotheses, the pathomechanism of RRD appears complex and is still not fully understood. In addition, no clinical guidelines exist concerning whether drug treatment should be continued upon manifestation of an associated radiation recall phenomenon. We present the case of a patient with docetaxel-induced RRD, which was successfully treated with topical steroids and systemic antihistamines; re-challenge to docetaxel did result in very mild remanifestation of skin reactions.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Histamine Antagonists; Humans; Male; Radiation Tolerance; Radiodermatitis; Taxoids; Treatment Outcome
PubMed: 27287082
DOI: 10.1007/s00066-016-0984-x -
Breast Cancer (Tokyo, Japan) Jan 2016We report a case of radiation recall dermatitis caused by trastuzumab. A 55-year-old woman with metastatic breast cancer received palliative first-line...
We report a case of radiation recall dermatitis caused by trastuzumab. A 55-year-old woman with metastatic breast cancer received palliative first-line trastuzumab/paclitaxel and a salvage partial mastectomy with lymph node dissection was subsequently performed. In spite of the palliative setting, the pathology report indicated that no residual carcinoma was present, and then she underwent locoregional radiotherapy to ensure a definitive response. After radiotherapy, she has maintained trastuzumab monotherapy. Nine days after the fifth cycle of trastuzumab monotherapy, dermatitis in previously irradiated skin developed, with fever. Radiation recall dermatitis triggered by trastuzumab is extremely rare. A high fever developed abruptly with a skin rash. This may be the first case of this sort to be reported.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Radiodermatitis; Trastuzumab
PubMed: 23543400
DOI: 10.1007/s12282-013-0462-6